PURPOSE: To compare parotid gland dose-volume response relationships in a large cohort of patients treated with intensity-modulated (IMRT) and conventional radiotherapy (CRT). METHODS AND MATERIALS: A total of 221 patients (64 treated with IMRT, 157 with CRT) with various head-and-neck malignancies were prospectively evaluated. The distribution of tumor subsites in both groups was unbalanced. Stimulated parotid flow rates were measured before and 6 weeks, 6 months, and 1 year after radiotherapy. Parotid gland dose-volume histograms were derived from computed tomography-based treatment planning. The normal tissue complication probability (NTCP) model proposed by Lyman was fit to the data. A complication was defined as stimulated parotid flow ratio <25% of the pretreatment flow rate. The relative risk of complications was determined for IMRT vs. CRT and adjusted for the mean parotid gland dose using Poisson regression modeling. RESULTS: One year after radiotherapy, NTCP curves for IMRT and CRT were comparable with a TD(50) (uniform dose leading to a 50% complication probability) of 38 and 40 Gy, respectively. Until 6 months after RT, corrected for mean dose, different complication probabilities existed for IMRT vs. CRT. The relative risk of a complication for IMRT vs. CRT after 6 weeks was 1.42 (95% CI 1.21-1.67), after 6 months 1.41 (95% CI; 1.12-1.77), and at 1 year 1.21 (95% CI 0.87-1.68), after correcting for mean dose. CONCLUSIONS: One year after radiotherapy, no difference existed in the mean dose-based NTCP curves for IMRT and CRT. Early after radiotherapy (up to 6 months) mean dose based (Lyman) models failed to fully describe the effects of radiotherapy on the parotid glands.
RCT Entities:
PURPOSE: To compare parotid gland dose-volume response relationships in a large cohort of patients treated with intensity-modulated (IMRT) and conventional radiotherapy (CRT). METHODS AND MATERIALS: A total of 221 patients (64 treated with IMRT, 157 with CRT) with various head-and-neck malignancies were prospectively evaluated. The distribution of tumor subsites in both groups was unbalanced. Stimulated parotid flow rates were measured before and 6 weeks, 6 months, and 1 year after radiotherapy. Parotid gland dose-volume histograms were derived from computed tomography-based treatment planning. The normal tissue complication probability (NTCP) model proposed by Lyman was fit to the data. A complication was defined as stimulated parotid flow ratio <25% of the pretreatment flow rate. The relative risk of complications was determined for IMRT vs. CRT and adjusted for the mean parotid gland dose using Poisson regression modeling. RESULTS: One year after radiotherapy, NTCP curves for IMRT and CRT were comparable with a TD(50) (uniform dose leading to a 50% complication probability) of 38 and 40 Gy, respectively. Until 6 months after RT, corrected for mean dose, different complication probabilities existed for IMRT vs. CRT. The relative risk of a complication for IMRT vs. CRT after 6 weeks was 1.42 (95% CI 1.21-1.67), after 6 months 1.41 (95% CI; 1.12-1.77), and at 1 year 1.21 (95% CI 0.87-1.68), after correcting for mean dose. CONCLUSIONS: One year after radiotherapy, no difference existed in the mean dose-based NTCP curves for IMRT and CRT. Early after radiotherapy (up to 6 months) mean dose based (Lyman) models failed to fully describe the effects of radiotherapy on the parotid glands.
Authors: Tim Dijkema; Cornelis P J Raaijmakers; Randall K Ten Haken; Judith M Roesink; Pètra M Braam; Anette C Houweling; Marinus A Moerland; Avraham Eisbruch; Chris H J Terhaard Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-07 Impact factor: 7.038
Authors: Tim Dijkema; Chris H J Terhaard; Judith M Roesink; Cornelis P J Raaijmakers; Petra A M van den Keijbus; Henk S Brand; Enno C I Veerman Journal: Radiat Oncol Date: 2012-06-15 Impact factor: 3.481
Authors: Patricia Doornaert; Wilko F A R Verbakel; Derek H F Rietveld; Ben J Slotman; Suresh Senan Journal: Radiat Oncol Date: 2011-06-16 Impact factor: 3.481
Authors: Rosario Astaburuaga; Hubert S Gabryś; Beatriz Sánchez-Nieto; Ralf O Floca; Sebastian Klüter; Kai Schubert; Henrik Hauswald; Mark Bangert Journal: Front Oncol Date: 2019-07-31 Impact factor: 6.244
Authors: Andrea Holt; Dirk Van Gestel; Mark P Arends; Erik W Korevaar; Danny Schuring; Martina C Kunze-Busch; Rob Jw Louwe; Corine van Vliet-Vroegindeweij Journal: Radiat Oncol Date: 2013-01-31 Impact factor: 3.481